DYRK1A As A Novel Target For Glioblastoma Therapies
Funder
National Health and Medical Research Council
Funding Amount
$620,294.00
Summary
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called DYRK1A (using ‘DYRK1A inhibitors’) kills glioblastoma cells. This therapeutic advantage is even greater when combined with drugs approved for other cancers. This project will develop new DYRK1A inhibitors and examine a novel combination treatment for glioblastoma patients. This could initiate a novel therapy that could significantly extend patients’ lives.
Isoform Selective PI3 Kinase Inhibitors For Cancer, Thrombosis And Inflammatory Disease
Funder
National Health and Medical Research Council
Funding Amount
$474,473.00
Summary
Inhibitors of the PI3 kinase family of enzymes have potential as therapeutics in diseases such as cancer, thrombosis and inflammatory disease. In this project the investigators will develop a new class of PI3 kinase inhibitors they have discovered, optimizing their pharmaceutical properties and evaluating them in models of disease. The aim is to develop a candidate for human clinical studies.
Chemical Biology Investigation Of Cell Death Processes: Development Of Molecular Probes Interfering With Necroptosis
Funder
National Health and Medical Research Council
Funding Amount
$630,736.00
Summary
Necroptotic programmed cell death has a key role in maintaining healthy tissue, and dysregulation of this process is associated with the pathology of infection and a range of chronic inflammation diseases for which there are few satisfactory treatments. In this project, we will discover small, drug like, molecules that interfere with the necroptosis pathway. These small molecules have the potential to become new therapeutics to treat these inflammatory diseases and will be invaluable probes to s ....Necroptotic programmed cell death has a key role in maintaining healthy tissue, and dysregulation of this process is associated with the pathology of infection and a range of chronic inflammation diseases for which there are few satisfactory treatments. In this project, we will discover small, drug like, molecules that interfere with the necroptosis pathway. These small molecules have the potential to become new therapeutics to treat these inflammatory diseases and will be invaluable probes to study this key biological pathway.Read moreRead less
Development Of Small Molecules For The Treament Of Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$684,379.00
Summary
Colon cancer remains one of the leading causes of cancer related deaths in Australia and in the developed world. Despite improvements in prevention and therapies, there remains a considerable need for efficacious therapeutic options. We have identified a lead compound inhibiting the growth of cancer cells. We will progress this series further toward clinical trials and aim to provide patients with a new orally available molecule with potent activity against colon cancer.
Developing Inhibitors Of An Essential Histidine Kinase In Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$578,352.00
Summary
Staphylococcus aureus (Golden staph) has been termed a "superbug" because of its persistent ability to acquire resistance to a wide range of antibiotics. Once considered primarily a hospital-acquired pathogen, many patients are now being infected with antibiotic-resistant Golden staph outside of hospitals. The primary aim of this research program is to develop new antibiotics to treat antibiotic-resistant strains of Staphylococcus aureus and related pathogens.